Boryung Pharmaceutical said Friday that it has signed a deal with Endure Medical, a Philippine-based pharmaceutical company, to export four of its anticancer drugs, during the 2018 CPhI Worldwide Convention in Spain.
|Boryung Pharmaceutical Global Sales Department Director Park Jae-rock (third from left) and Endure Medical BD&RA team Head Jonas Angara Depalac hold up their agreement at CPhI Worldwide Convention in Madrid, Spain, Thursday.|
The four are EP mycin, AD mycin, Oxalitin and Neoplatin.
Under the agreement, Boryung will supply 5 billion won ($4.4 million) worth of drugs for three years.
The company is already shipping its anticancer drugs to various Southeast Asian countries including Thailand, Indonesia and Vietnam. Based on its export in the region, Boryung plans to expand their business to Africa and South America.
<© Korea Biomedical Review, All rights reserved.>